3T Biosciences is an immunotherapy company focused on discovering and developing next-generation therapies with curative potential based on its immune-response guided target discovery approach. 3T Biosciences' 3T-TRACE platform technology is designed to overcome the challenges of advancing T-cell receptor (TCR)-based therapeutics.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/25/22 | $40,000,000 | Series A |
Westlake Village BioPartners | undisclosed |
